John M. Kane, MD

home / authors / john-m-kane-md

Articles

Cognitive Issues in Schizophrenia Remain a Challenge

John M. Kane, MD

April 3rd 2025

How does John Kane, MD, address issues of cognition in schizophrenia?

A Welcome Action: Removal of the REMS Requirement for Clozapine

John M. Kane, MD

April 2nd 2025

John Kane, MD, believes the removal of the REMS requirement for clozapine could help improve utilization for this "grossly underutilized" drug.

LB-102: A New, Novel Drug for Schizophrenia

John M. Kane, MD

April 1st 2025

John Kane, MD, shares why you should be paying attention to LB-102 for the treatment of schizophrenia.

LB-102 for the Treatment of Acutely Exacerbated Schizophrenia: Insights From the Principal Investigator

John M. Kane, MD

March 31st 2025

In this exclusive interview with Psychiatric Times, John Kane, MD, shares more on the new positive data on LB-102 for the treatment of acutely exacerbated schizophrenia.

Erin Crown, PA-C, CAQ-Psychiatry, and John M. Kane, MD, experts on schizophrenia

Potential Novel Schizophrenia Treatments

John M. Kane, MD;Erin Crown, MHS, PA-C, Psych-CAQ

May 9th 2024

A comprehensive discussion on new treatment options for patients with schizophrenia, highlighting the potential for earlier intervention to optimize treatment outcomes.